Navigation Links
Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis

Levodopa Remains the Most Widely Prescribed Drug for Parkinson's Disease,

According to a New Report from Decision Resources

WALTHAM, Mass., Aug. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that 61 percent of newly diagnosed Parkinson's disease patients do not receive any drug treatment in the first year of diagnosis. According to the new report entitled Treatment Algorithms for Parkinson's Disease, failure of newly diagnosed Parkinson's disease patients to receive pharmacological treatment within the first 12 months of diagnosis likely occurs as a result of patients' decisions to delay treatment until symptoms become sufficiently troublesome. Furthermore, because the guidelines of the American Academy of Neurology (AAN) do not define specific time periods for when treatment should be initiated, patients may be reluctant to begin levodopa therapy, such as with Bristol Myers Squibb's Sinemet, knowing that side-effects will arise, specifically motor response complications.

Levodopa provides greater motor benefit than dopamine agonists, such as GlaxoSmithKline's Requip or Boehringer Ingelheim's Mirapex, but inevitably results in the development of levopoda-induced side effects, including dyskinesias, off time (sudden motor switches between normal and Parkinson movements) and wearing-off complications (shortened periods of benefit after each levodopa use).

"Levodopa continues to be the gold-standard Parkinson's disease treatment, with 99% of neurologists and 95% of PCPs we surveyed currently prescribing it in their Parkinson's disease practice," said Nicole Westphal, Ph.D., analyst at Decision Resources. "However, first-line levodopa use will decrease over the next two years as physicians increasingly use levodopa-sparing approaches. Patient demand for well-tolerated, levodopa-sparing treatments will continue to drive increases in dopamine agonist patient share first line. Patients will benefit from the introduction of new agents, including new formulations and line extensions within the dopamine agonist class. However, GlaxoSmithKline's Requip will face generic competition in 2008, so the overall market for dopamine agonists will begin to diminish, despite the launch of new agents in this class."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides:

-- Summary of U.S. medical practice based on interviews with leading

experts in the field

-- Qualitative diagnosis/referral/treatment algorithm for the

United States

-- Drug usage by lines of therapy (1st, 2nd, 3rd line)

-- Discussion of key freeform combinations by lines of therapy

-- Product share (class and specific compound level) within each line of

therapy (1st, 2nd, 3rd line)

-- Progression of therapy from key 1st line products

-- Pathway to key therapies from previous therapies

-- Qualitative analysis of 2-year forecast incorporating upcoming

launches, changes in reimbursement, etc.

About Decision Resources

Decision Resources, Inc., ( is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.


SOURCE Decision Resources

Copyright©2007 PR Newswire.

Related medicine technology :

1. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer
6. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
7. Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate Dependency Treatment Are Mothers
8. Eighty-one Percent of U.S. Adults say that Birth Control Pills and Procedures Should Be Covered by Health Insurance
9. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
10. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
11. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
Post Your Comments:
(Date:11/30/2015)... BOSTON , November 30, 2015 /PRNewswire/ ... potential new medicines directed at up to 10 G ... --> PFE ) to research and develop potential ... receptor (GPCR) targets across multiple therapeutic areas. --> ... discovery and development company and wholly-owned subsidiary of Sosei ...
(Date:11/29/2015)... Nov. 29, 2015  Strengthening its leadership in connected ... PHIA) today announced IntelliSpace Portal 8.0 , the ... visualization platform that helps radiologists detect, diagnose and follow-up ... Radiological Society of North America Annual Meeting (RSNA) ... 8.0 helps address the changing demands in radiology that ...
(Date:11/29/2015)... 2015   National Decision Support Company (NDSC) continues ... including notable statewide implementations. As a result, ordering ... Select, more than 1 million times per month—all ... Select provides real-time feedback on the most appropriate ... been implemented at over 100 healthcare systems nationally, ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen Plastic ... surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, one ... Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global medical ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... alliance around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair in ... TIGR® Matrix is a long-term resorbable surgical mesh intended to support and reinforce ...
(Date:11/30/2015)... ... ... TransPack Volume 6 features 30 customizable transitions created exclusively for use within ... with blur & drop shadow options. Utilize the controls in the inspector window ... the next with TransPack's easily customizable styles. , TransPack Volume 6 features ...
(Date:11/30/2015)... ... November 30, 2015 , ... Workstation solutions provider ... 30 HealthPostures’ dealers located throughout the United States, is OneStop Ergonomics. The addition ... industrial, manufacturing and government workers and organizational leaders that are introduced to innovative ...
(Date:11/29/2015)... ... November 30, 2015 , ... Gift ideas for ... Beauty NATURALS®. All products are available on Amazon or its webstore. , "We ... serums and USDA Certified Organic Sesame Oil for Oil Pulling," says Kathy Heshelow, ...
Breaking Medicine News(10 mins):